adjuvant news from FierceBiotech
News
Feds ok Iomai Phase II adjuvant patch study
Health and Human Services is giving Iomai the green light to do a mid-stage dose ranging study of its adjuvant patch for bird flu vaccine. HHS provided a $128 million contract backing Iomai's effort Read more...
ALSO NOTED: Visiomed, Clinical Cell Culture to merge; Genzyme wants to reopen merger vote; Vical touts adjuvant data; and much
> Visiomed Group and Clinical Cell Culture are merging into a $27 million biotech company. Read more...
Press Release: Novartis Gains Access to Intercell's Key Technologies and Vaccines Programs
Press Release: Novartis Gains Access to Intercell's Key Technologies and Vaccines Programs
Read more...Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
Read more...Press Release: GSK Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
Press Release: GSK Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
Read more...Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Read more...Bird flu vaccine effective in animal trial
Vical says its bird flu vaccine proved 100 percent effective in protecting ferrets from bird flu. Vical announced earlier that two doses of DNA vaccine was effective in protecting mice and ferrets. Vical's vaccine candidate is mixed with Vaxfectin adjuvant and viral proteins. Vical says it wants to begin human trials as soon as possible.
- here's the AP …
Read more...Low-dose bird flu vaccine effective in trial
China's Sinovac Biotech says that its low-dose bird flu vaccine proved effective in generating an immune response from 80 percent of the 120 volunteers taking part in the trial. The vaccine was developed by using a part of the whole H5N1 virus and combining it with an adjuvant that increases the potency of the therapy. Researchers have been scrambling to find a low-dose vaccine that might work against bird flu. A low-dose vaccine would make it possible to produce enough vaccines to …
Read more...ALSO NOTED: Takeda, Galaxy Biotech ink licensing deal; Protalex raises $15.2M in private placement; and much more...
> Antigenics has expanded its licensing and supply deals for QS-21 Stimulon adjuvant with a vaccine division of GlaxoSmithKline. Release
> New Hope, PA-based Protalex has raised approximately $15.2 million in a private placement of 6.1 million shares of common stock. …
Read more...GSK upbeat on bird flu vaccine trials
The race for a new vaccine to fight a human outbreak of H5N1 has heated up as GlaxoSmithKline says it has begun human trials of two experimental bird flu vaccines. Researchers have made this new vaccine with an that boosts the vaccine's effectiveness. It is also boosting the hopes of GSK researchers, who believe that the new vaccines may be much more effective at combating bird flu than a competing vaccine that is being advanced by Sanofi-Aventis. Sanofi researchers said earlier this week …
Read more...Get more adjuvant coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends